[Platelet aggregation and P-selectin concentration in patients on peritoneal dialysis treated with erythropoietin].
In chronic renal failure disturbances of hemostasis are predominantly due to the defective platelet function and platelet/vessel wall interactions. Erythropoietin, used for treatment of renal anemia, affect hemostasis in dialyzed patients. The aim of the work was to assess platelet aggregation and P-selectin concentration in patients on continuous ambulatory peritoneal dialysis (CAPD) during erythropoietin therapy. The studied were performed on 12 CAPD patients, administered with subcutaneous erythropoietin in a dose of 2000 U three times a week for 3 months. Hemoglobin, hematocrit and erythrocyte count increased significantly after 1 month of the treatment. Platelet aggregation in platelet-rich plasma induced by collagen, ristocetin and serotonin increased significantly after 3 months of erythropoietin therapy when compared to the baseline values. Whole blood platelet aggregation and P-selectin concentration did not change significantly during 3 months of erythropoietin therapy. Erythropoietin treatment in CAPD patients did not affect significantly platelet aggregation and activation.
Małyszko
J
J
Klinika Nefrologii i Chorób Wewnetrznych AM w Białymstoku.
Suchowierska
E
E
Pawlak
K
K
Małyszko
J S
JS
Myśliwiec
M
M
D000328:Adult; D000368:Aged; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000032:analysis*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D010974:Platelet Aggregation / Q000502:physiology*
D019007:P-Selectin; D004921:Erythropoietin